{
    "Symbol": "IQV",
    "AssetType": "Common Stock",
    "Name": "IQVIA Holdings Inc",
    "Description": "IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.",
    "CIK": "1478242",
    "Exchange": "NYSE",
    "Currency": "USD",
    "Country": "USA",
    "Sector": "TRADE & SERVICES",
    "Industry": "SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH",
    "Address": "4820 EMPEROR BLVD., DURHAM, NC, US",
    "FiscalYearEnd": "December",
    "LatestQuarter": "2022-12-31",
    "MarketCapitalization": "35532452000",
    "EBITDA": "2571000000",
    "PERatio": "33.61",
    "PEGRatio": "1.475",
    "BookValue": "31.05",
    "DividendPerShare": "0",
    "DividendYield": "0",
    "EPS": "5.68",
    "RevenuePerShareTTM": "76.81",
    "ProfitMargin": "0.0757",
    "OperatingMarginTTM": "0.129",
    "ReturnOnAssetsTTM": "0.0465",
    "ReturnOnEquityTTM": "0.185",
    "RevenueTTM": "14410000000",
    "GrossProfitTTM": "5028000000",
    "DilutedEPSTTM": "5.68",
    "QuarterlyEarningsGrowthYOY": "-0.267",
    "QuarterlyRevenueGrowthYOY": "0.028",
    "AnalystTargetPrice": "258.32",
    "TrailingPE": "33.61",
    "ForwardPE": "18.59",
    "PriceToSalesRatioTTM": "2.706",
    "PriceToBookRatio": "7.24",
    "EVToRevenue": "3.497",
    "EVToEBITDA": "17.39",
    "Beta": "1.407",
    "52WeekHigh": "254.94",
    "52WeekLow": "165.75",
    "50DayMovingAverage": "218.35",
    "200DayMovingAverage": "212.75",
    "SharesOutstanding": "186141000",
    "DividendDate": "None",
    "ExDividendDate": "None"
}